公开(公告)号：US20170246273A1

公开(公告)日：2017-08-31

申请号：US15325955

申请日：2015-07-17

Applicant: Advaxis, Inc. ,  City of Hope

Inventor： Anu Wallecha ,  Robert Petit ,  Joshua Ellenhorn ,  Don J. Diamond

IPC: A61K39/00 ,  C12N9/90 ,  A61K39/385 ,  C12N15/85 ,  C07K14/195 ,  C07K14/47

CPC classification number: A61K39/0011 ,  A61K35/74 ,  A61K39/385 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/572 ,  A61K2039/6037 ,  A61P35/00 ,  C07K14/195 ,  C07K14/4703 ,  C07K2319/40 ,  C07K2319/55 ,  C12N9/90 ,  C12N15/85 ,  C12N2800/107 ,  C12N2820/55 ,  C12Y501/01001

Abstract: Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant Listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.

公开(公告)号：US20170239336A1

公开(公告)日：2017-08-24

申请号：US15439649

申请日：2017-02-22

Applicant: Maurizio ZANETTI

Inventor： Maurizio ZANETTI

IPC: A61K39/00 ,  A61K38/45 ,  A61K39/39

CPC classification number: A61K39/0005 ,  A61K38/45 ,  A61K39/015 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/6037 ,  C12N2710/20034 ,  C12N2760/18434 ,  C12N2770/24134

Abstract: Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing T cell epitopes that have been altered to increase immunogenicity. The methods comprise administration of the polypeptides or nucleic acids, such as DNA or RNA encoding the polypeptides, to individuals afflicted with, or at risk of, developing cancer.

公开(公告)号：US20170209563A1

公开(公告)日：2017-07-27

申请号：US15329205

申请日：2015-07-24

Applicant: BIOSYNTH S.R.L.

Inventor： Massimo PORRO

IPC: A61K39/02 ,  A61K39/108 ,  A61K39/112

CPC classification number: A61K39/107 ,  A61K39/0258 ,  A61K39/0275 ,  A61K47/646 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/575 ,  A61K2039/6037 ,  A61K2039/627 ,  A61K2039/70 ,  Y02A50/474 ,  Y02A50/482 ,  Y02A50/484

Abstract: The present invention refers to new glycoconjugate antigens expressing built-in multiple epitopes and to polyvalent glycoconjugate vaccines intended for the protection of mammalians, and particularly for the protection of the human population from enteropathogenic bacteria, such as the Gram-positive anaerobic bacterium Clostridium difficile and the Gram-negative bacteria Salmonella typhi, Escherichia Coli, Vibrio Cholerae, Shigella flexneri, Salmonella typhimurium, Salmonella enteritidis, Salmonella paratyphi A, Shigella sonnei, Shigella dysenteriae, Salmonella cholerasuis, Klebsiella, Enterobacter, Pseudomonas aeruginosa and/or from viral gastrointestinal infections due to human noroviruses.

公开(公告)号：US09700612B2

公开(公告)日：2017-07-11

申请号：US14628844

申请日：2015-02-23

Applicant: GlycoVaxyn AG

Inventor： Michael T. Kowarik ,  Michael L. Wetter ,  Stefan J. Kemmler ,  Micha A. Häuptle ,  Veronica Gambillara ,  Manuela Mally

IPC: A61K47/48 ,  A61K39/108 ,  C07K14/21 ,  A61K39/02 ,  C08B37/00 ,  A61K39/00 ,  C07K14/245

CPC classification number: A61K39/0258 ,  A61K39/02 ,  A61K47/646 ,  A61K2039/55583 ,  A61K2039/6037 ,  A61K2039/6087 ,  A61K2039/70 ,  C07K14/21 ,  C07K14/245 ,  C08B37/0063 ,  C08B37/0066 ,  Y02A50/47

Abstract: Provided herein is a novel E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells comprising enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates comprise O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, comprising O25B and/or bioconjugates comprising O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further comprise one or more additional bioconjugates.

公开(公告)号：US20170106063A1

公开(公告)日：2017-04-20

申请号：US15294618

申请日：2016-10-14

Applicant: Peter BLACKBURN ,  Stephen GRIMES

Inventor： Peter BLACKBURN ,  Stephen GRIMES

IPC: A61K39/00

CPC classification number: A61K39/0007 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/6037 ,  A61K2039/6081 ,  C07K14/4711 ,  Y02A50/466

Abstract: A safe and effective vaccine to prevent, slow, halt or reverse progression of Alzheimer's disease in human patients is disclosed. The vaccine includes Aβ1-42 or an beta amyloid self epitope (e.g. Aβ1-15, or other 7-mer or 15-mer peptide epitopes derived from A↑1-42) conjugated to an immunogenic carrier (e.g. DT) formulated in a water-in-oil Th2-biased adjuvant/delivery system.

公开(公告)号：US09616139B2

公开(公告)日：2017-04-11

申请号：US14128958

申请日：2012-07-11

Applicant: Edward T. Ryan ,  Pavol Kovac ,  Firdausi Qadri ,  Peng Xu ,  Stephen B. Calderwood ,  Willie Frank Vann ,  Dwight Christopher Peterson

Inventor： Edward T. Ryan ,  Pavol Kovac ,  Firdausi Qadri ,  Peng Xu ,  Stephen B. Calderwood ,  Willie Frank Vann ,  Dwight Christopher Peterson

IPC: A61K38/02 ,  A61K47/48 ,  A61K39/02 ,  C08B37/00 ,  C08H1/00 ,  C08L89/00 ,  A61K9/00 ,  A61K39/08 ,  A61K39/00

CPC classification number: A61K47/4833 ,  A61K9/0019 ,  A61K39/08 ,  A61K39/107 ,  A61K47/646 ,  A61K2039/55544 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  C08B37/00 ,  C08H1/00 ,  C08L89/00 ,  Y02A50/472 ,  Y02A50/478 ,  Y02A50/484

Abstract: The disclosure provides directly conjugated polysaccharide vaccine molecules and methods related thereto.

公开(公告)号：US20170081642A1

公开(公告)日：2017-03-23

申请号：US15288409

申请日：2016-10-07

Applicant: Bavarian Nordic A/S

Inventor： Paul Chaplin ,  Robin Steigerwald

IPC: C12N7/00 ,  C07K14/32 ,  C07K14/33

CPC classification number: C07K14/32 ,  A61K39/07 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/575 ,  A61K2039/6037 ,  C07K2319/55 ,  C12N15/86 ,  C12N2710/24043 ,  C12N2710/24134 ,  C12N2710/24143

Abstract: The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment C for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment C (TTC) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject.

公开(公告)号：US20170058005A1

公开(公告)日：2017-03-02

申请号：US15308234

申请日：2015-04-30

Applicant: IMPERIAL INNOVATIONS LTD

Inventor： Daniel ALTMANN

IPC: C07K14/32 ,  C12N7/00 ,  A61K39/07

CPC classification number: C07K14/32 ,  A61K39/07 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/6037 ,  C12N7/00 ,  C12N2710/10043

Abstract: The invention provides a polypeptide that is not full length Anthrax Lethal Factor (LF) or a fusion thereof, comprising or consisting of one or more sequences selected from the group of LF457-486, LF467-486, LF101-120, LF171-190, LF241-260, LF251-270, LF261-280, LF281-300, LF457-476, LF467-486, LF547-567, LF574-593, LF584-603, LF594-613, LF604-623, LF644-663, LF674-693, LF694-713 and LF714-733, and further provides a polynucleotide encoding such a polypeptide or a vector comprising such a polynucleotide, optionally wherein the vector is an adenoviral vector. A method for vaccinating a subject against anthrax or B. anthracis comprising the step of exposing the subject to a polypeptide, polynucleotide, vector, host cell or composition of the invention, optionally wherein the subject is a human or a livestock or domestic animal.

Abstract translation: 本发明提供了不是全长炭疽致死因子（LF）或其融合物的多肽，其包含或由选自以下的一种或多种序列组成：LF457-486，LF467-486，LF101-120，LF171-190， LF241-260，LF251-270，LF261-280，LF281-300，LF457-476，LF467-486，LF547-567，LF574-593，LF584-603，LF594-613，LF604-623，LF644-663，LF674- 693，LF694-713和LF714-733，并且还提供了编码这种多肽或包含这种多核苷酸的载体的多核苷酸，任选其中载体是腺病毒载体。 用于针对炭疽或炭疽芽孢杆菌接种受试者的方法，包括将受试者暴露于本发明的多肽，多核苷酸，载体，宿主细胞或组合物的任选其中所述受试者是人或家畜或家畜的步骤。

公开(公告)号：US20170056490A1

公开(公告)日：2017-03-02

申请号：US15351847

申请日：2016-11-15

Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.

Inventor： Ralph Leon BIEMANS ,  Dominique BOUTRIAU ,  Philippe DENOEL ,  Pierre DUVIVIER ,  Carine GORAJ

IPC: A61K39/085 ,  A61K47/48

CPC classification number: A61K39/085 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/545 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/70

Abstract: This application relates to immunogenic compositions comprising a Staphylococcus aureus Type 5 capsular saccharide conjugated to a carrier protein to form a S. aureus Type 5 capsular saccharide conjugate.

Abstract translation: 本申请涉及包含与载体蛋白缀合以形成金黄色葡萄球菌5型荚膜糖缀合物的金黄色葡萄球菌5型荚膜糖的免疫原性组合物。

公开(公告)号：US09580514B2

公开(公告)日：2017-02-28

申请号：US14400684

申请日：2013-03-14

Applicant: Genentech, Inc.

Inventor： Sunil Bhakta ,  Meredith Hazen ,  Jo-Anne S Hongo ,  Jagath R Junutula ,  Isidro Hotzel ,  Yonglei Shang ,  Shang-Fan Yu

IPC: A61K39/395 ,  C07K16/30 ,  A61K47/48 ,  A61K51/10 ,  C12Q1/68 ,  G01N33/574 ,  A61K39/00

CPC classification number: C07K16/30 ,  A61K47/6803 ,  A61K47/6809 ,  A61K47/6817 ,  A61K47/6855 ,  A61K51/1051 ,  A61K2039/505 ,  A61K2039/6037 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/77 ,  C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57415 ,  G01N33/57423 ,  G01N2333/47 ,  G01N2500/02

Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. In certain aspects, the isolated nucleic acid molecule comprises a nucleotide sequence having at least about 80% nucleic acid sequence identity, alternatively at least about 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% nucleic acid sequence identity, to (a) a DNA molecule encoding a full-length TAT polypeptide having an amino acid sequence as disclosed herein, a TAT polypeptide amino acid sequence lacking the signal peptide as disclosed herein, an extracellular domain of a transmembrane TAT polypeptide, with or without the signal peptide, as disclosed herein.

Abstract translation: 本发明涉及用于哺乳动物肿瘤诊断和治疗的物质组合物，以及使用这些物质组合物的方法。 在某些方面，分离的核酸分子包含具有至少约80％核酸序列同一性，或至少约81％，82％，83％，84％，85％，86％，87％，88 ％，89％，90％，91％，92％，93％，94％，95％，96％，97％，98％，99％或100％的核酸序列同一性。 如本文公开的具有本文公开的氨基酸序列的全长TAT多肽，缺乏本文公开的信号肽的TAT多肽氨基酸序列，跨膜TAT多肽的胞外结构域，具有或不具有信号肽。